Metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease also decreases at thyroid (original) (raw)

• Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure.J Auton Nerv Syst 1994;49:81–84.
  Article PubMed CAS Google Scholar
• Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific.Eur J Nucl Med 2000; 27: 566–573.
  Article PubMed CAS Google Scholar
• Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuweit T, et al. Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT.J Neurol Sci 2000; 175: 3–12.
  Article PubMed CAS Google Scholar
• Reinhardt MJ, Jungling FD, Krause TM, Braune S. Scinti-graphic differentiation between two forms of primary dys-autonomia early after onset of autonomie dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake.Eur J Nucl Med 2000; 27: 595–600.
  Article PubMed CAS Google Scholar
• Orimo S. Usefulness of MIBG myocardial scintigraphy to differentiate parkinsonism and dementia with Lewy bodies.Neurol Med 2003; 58: 544–554. (in Japanese)
  Google Scholar
• Taki J, Yoshita M, Yamada M, Tonami N. Significance of123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease.Ann Nucl Med 2004; 18: 453–461.
  PubMed Google Scholar
• Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease.Neurology 2002; 58: 1247–1255.
  PubMed CAS Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases.J Neurol Neurosurg Psychiatry 1992; 55: 181–184.
  PubMed CAS Google Scholar
• Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy.J Neurol Sci 1999; 163: 94–98.
  Article PubMed CAS Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality.Neurology 1967; 17: 427–442.
  Article PubMed CAS Google Scholar
• Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease.Neurology 2002; 58: 1247–1255.
  PubMed CAS Google Scholar
• Yamamoto M.Parkinson ’s disease: Advances in pathology and autonomie nervous system. Tokyo; Chugai Igakusha 2004. (in Japanese)
  Google Scholar
• Dae MW, De Marco T, Botvinick EH, O’Connell JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts—implications for clinical studies.J Nucl Med 1992; 33: 1444–1450.
  PubMed CAS Google Scholar
• Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis.J Nucl Med 1993; 34: 57–60.
  PubMed CAS Google Scholar
• Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants.J Nucl Med 1989; 30: 1182–1191.
  PubMed CAS Google Scholar
• Sisson JC, Bolgos G, Johnson J. Measuring acute changes in adrenergic nerve activity of the heart in the living animal.Am Heart J 1991; 121: 1119–1123.
  Article PubMed CAS Google Scholar
• Jager WADH, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans.J Neurol Neurosurg Psychiatry 1960; 23: 283–290.
  Article Google Scholar
• Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart.J Nucl Med 1986; 27: 84–89.
  PubMed CAS Google Scholar
• Hirayama M, Kato R. The clinical assessment of peripheral sympathetic function using123I-metaiodobenzylguanidine.Neurol Med 1997; 47: 158–163.
  Google Scholar
• Takahashi N, Inoue T, Oka T. Quantitative evaluation of cardiac disease using201Tl,99mTc-MIBI,123I-MIBG and123I-BMIPP single photon emission computed tomography.Jpn J Diag Imag 2002; 22: 749–759.
  Google Scholar
• Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man.J Nucl Med 1987; 28: 1625–1636.
  PubMed CAS Google Scholar
• Langston JW, Forno LS. The hypothalamus in Parkinson’s disease.Ann Neurol 1978; 3: 129–133.
  Article PubMed CAS Google Scholar
• Rajput AH, Rozdilsky B. Dysautonomia in parkinsonism. A clinicopathological study.J Neurol Neurosurg Psychiatry 1976; 39: 1092–1100.
  PubMed CAS Google Scholar
• Matthews MR. Autonomie ganglia in multiple system atrophy and pure autonomie failure. In: Bannister R, Mathias CJ (eds),Autonomie failure, 3rd ed. Oxford; Oxford University Press, 1992:593–621.
  Google Scholar
• Chiueh CC, Zukowska-Grojec Z, Kirk KL, Kopin IJ. 6-Fluorocatecholamines as false adrenergic neurotransmitters.J Parmacol Exp Ther 1983; 225: 529–533.
  CAS Google Scholar
• Goldstein DS, Holmes C, Stuhlmuller JE, Lenders JW, Kopin IJ. 6-[18F]fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympatho-neural function-studies in normal humans.Clin Auton Res 1997; 7: 17–29.
  Article PubMed CAS Google Scholar